argenx

argenx is a global immunology company that develops antibody-based therapies for severe autoimmune diseases and other serious conditions. Its mission is to translate immune system biology into treatments that make a difference for patients. Its key products are VYVGART (efgartigimod alfa), approved for generalized myasthenia gravis and other indications, and VYVGART Hytrulo, a subcutaneous formulation.